Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: predictive-oncology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | $3.00 | Buy | H.C. Wainwright |
| 6/30/2021 | $5.00 | Buy | HC Wainwright & Co. |
SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)
SC 13G - Predictive Oncology Inc. (0001446159) (Subject)
H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00
HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00
Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00
PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i
PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY. Management's presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform. The Predictive Oncology management team will host one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to request a meeting. About Predictive Onc
Study further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples Global biospecimen market valued at $4.4 billion in 2023, expected to grow at an annual CAGR of more than 13%, reaching $11.7 billion by 20311 PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today announced the results of a successful study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples stored within the Company's proprietary biobank. Importantly, with more than 20 years of longitudinal patient a
PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s
Findings demonstrate real-world applications of Company's AI platform to support biomarker discovery, clinical trial optimization and target validation Proprietary tool accounts for patient heterogeneity and increases Probability of Technical Success PITTSBURGH, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today announced that it has expanded the available applications for its platform to account for patient heterogeneity, de-risk drug discovery, and accelerate pipeline development. Responding to the historically high failure rate in drug development in Phase II and Phase III clinical trials, the Company is u
PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File No. 333-267689), Form S-3 (File No. 2
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology Biomarker discovery market estimated by third party research to be $51.5 billion in 2024 PITTSBURGH, July 25, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that it is expanding its AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology. Predictive Oncology's biomarker discovery initiative stems, in part, from results obtained in the retrospective ovarian cancer study with UP
Company files expansive intellectual property protection for "Membrane Protein Factory" to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annually through 20301 PITTSBURGH, June 11, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (GPCRs). GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating inv
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive Officer, is scheduled to deliver a company overview presentation at the BIO International Convention 2024, which is being held June 3-6 in San Diego. "We are very pleased to participate in this year's Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world," stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. "With our unique portfolio of assets, which includes advanced AI and active machine learning capabilities, a CLIA-
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
10-Q - Predictive Oncology Inc. (0001446159) (Filer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
EFFECT - Predictive Oncology Inc. (0001446159) (Filer)
S-3 - Predictive Oncology Inc. (0001446159) (Filer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
10-Q - Predictive Oncology Inc. (0001446159) (Filer)
D - Predictive Oncology Inc. (0001446159) (Filer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i
PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s
PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2024, and provided a corporate update. The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter. Q1 2024 and Recent Highlights: Announced that an abstract detailing results of the recent study that Predictive Oncol
PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the first quarter ended March 31, 2024 before the markets open on Wednesday, May 15, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas
PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2023, and provided a corporate update. The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023. Q4 2023 and Recent Highlights: Reported meaningful progress with FluGen collaboration designed
PITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and nine months ended September 30, 2023, and provided a corporate update. The company reported a net loss of $3.2 million on total net revenue of $0.7 million for the third quarter 2023. Q3 2023 and Recent Highlights: Successfully delivered actionable results of first campaign with Cancer Research
EAGAN, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the third quarter ended September 30th, 2023 before the markets open on Tuesday, November 14, 2023. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. on that day. Live Confere
PITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023. Q2 2023 and Recent Highlights: Initiated PEDAL-Cancer Research Horizons collaboration for the analysis of dru
EAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2023 after the markets close on Thursday, August 10, 2023. The company will host a corporate update conference call and live audio webcast at 5:30 p.m. on that day. Live Conference Ca
EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas
EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed Business Advisory Board (BAB). "I am very pleased to welcome Dr. Harris to our new Business Advisory Board," said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. "As we continue
EAGAN, Minn., May 02, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of healthcare commercial and business development veteran Veena Rao, Ph.D., MBA, to its Board of Directors. Dr. Rao currently serves as Chief Business Officer of Portal Instruments, where she leads the identification, evaluation, and negotiation of
EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, is pleased to announce the appointment of Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board. In this role, Dr. Reinhard will serve alongside other key thought leaders in their respective fields to guide the Company's scientific initiatives and growth strategy.
EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, Dr. Bush will spearhead the company's strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company's senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company's biopharma partner
EAGAN, Minn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) today announced the appointment of Robert F. Murphy, Ph.D., to the company's Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the company's scientific initiatives and growth strategy. As a pioneer in the field of machine learning and analytics for biological data, Dr. Murphy is an expert in developing algorithms and models to understand biological systems and relationships. He was founding head of the Computational Biology Department at Carnegie Mellon University (CMU), and led the development of CORE™, the machine learning technology
EAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) today announced the appointment of Marc Malandro, Ph.D., to the company's Scientific Advisory Board where he will serve alongside other key thought leaders in their respective fields to guide the company's scientific initiatives and growth strategy. A highly regarded scientific leader with significant experience in business, law and philanthropy, Dr. Malandro currently serves as the Vice President of Operations for Science at the Chan Zuckerberg Initiative, where he is part of the team that partners, supports and builds novel advances and tools to enable and accelerate biomedical research. "Marc is not
EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (NASDAQ:GRTS). Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named invento
EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights from the quarter include: Raymond F. Vennare, has been appointed as Chief Executive Officer and Chairman of the Board. An accomplished executive with more than three decades of experience, Mr. Vennare has a long history of building, launching and leading biotech companies.Predictive Oncology continues to gain traction with potential partners with its breakthrough solution at a pivotal time in drug di
EAGAN, Minn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI) is pleased to announce the appointment of David S. Smith, JD, to the company's Board of Directors. Mr. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the therapeutic use of human tissue and cells. He has extensive transactional experience, venture financings and regulatory matters for life sciences companies and investors. "In the world of life sciences, specifically in terms of intellectual property and the scientific and commercial use of human tissue, David Smith is both a legal authority and a key thought leader.
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 40,064.06 while the NASDAQ fell 1.25% to 17,124.88. The S&P 500 also fell, dropping, 0.38% to 5,406.26. Check This Out: Jim Cramer: This Tech Stock Is ‘Absolutely Terrific,’ But Jumia? It’s Not Making A Lot Of Money Leading and Lagging SectorsReal estate shares jumped by 1.4% on Wednesday. In trading on Wednesday, information technology shares fell by 2.5%. Top Headline Honeywell International Inc. (NASDAQ:HON) reported second-quarter results and lowered FY24 EPS guidance. Adjusted EPS was $2.49 (+8% Y/Y), beat
EW: -24% | Edwards Lifesciences shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company acquired JenaValve and Endotronix. MXL: -27% | MaxLinear shares are trading lower after the company reported worse-than-expected Q2 financial results. POAI: 117% | Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Company files expansive intellectual property protection for "Membrane Protein Factory" to produce purified and biologically active membrane proteins for drug developmentExternal sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annually through 2030
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results. Bank of Montreal posted quarterly adjusted earnings of C$2.59 per share, missing market estimates of C$2.77 per share. The company's quarterly sales came in at C$7.988 billion missing expectations of C$8.046 billion, according to data from Benzinga Pro. Bank of Montreal shares declined 7.1% to $89.32 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) shares jumped 82.8% to $0.3799 a day after it received the nod from the U.S. Patent And Trademark O
Shares of Ooma, Inc. (NYSE:OOMA) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and issued strong guidance for the second quarter. The company also issued FY25 adjusted EPS guidance above estimates. Ooma shares jumped 17% to $9.24 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) rose 130.2% to $0.4789 in today's pre-market trading after the company announced that it received a notice of allowance for its U.S. patent application 17/572,387 titled “INTRAGASTRIC DEVICE (FOR TREATING OBESITY)” Scorpius Holdings,
Shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) fell sharply during Tuesday's session after the company announced the pricing of a $12 million public offering. Applied DNA Sciences shares tumbled 67.5% to $0.6468 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Sharps Technology, Inc. (NASDAQ:STSS) shares climbed 207% to $0.6579 after jumping around 13% on Friday. Insmed Incorporated (NASDAQ:INSM) jumped 110% to $46.20 after the company announced topline results from ASPEN Phase 3 study met its primary endpoint. Pineapple Energy Inc. (NASDAQ:PEGY) shares gained 91.5% to $0.3411 after the company on Friday announced its SUNation subsidiar
Gainers Sharps Technology (NASDAQ:STSS) stock rose 140.0% to $0.51 during Tuesday's regular session. The company's market cap stands at $8.0 million. Insmed (NASDAQ:INSM) stock moved upwards by 112.72% to $46.8. The company's market cap stands at $6.9 billion. Calliditas Therapeutics (NASDAQ:CALT) shares moved upwards by 69.26% to $37.95. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out 3 days ago. Predictive Oncology (NASDAQ:POAI) shares rose 36.54% to $2.14. The company's market cap stands at $8.7 million. Semler Scientific (NASDAQ:SMLR) stock moved upwards by 28.55% to $29.98. The company's market cap stands at $211.8 million. Exicure (NASDAQ:XCUR
Predictive Oncology Inc (NASDAQ:POAI) shares are trading higher by 46.6% to $2.30 during Tuesday’s session after the company announced positive results from a retrospective study conducted with UPMC Magee-Womens Hospital. These results will be presented at the 2024 ASCO Annual Meeting in Chicago. The study aimed to develop machine learning (ML) models to predict short-term (two-year) and long-term (five-year) survival outcomes in ovarian cancer patients. Per the company, high grade serous ovarian cancer is challenging to treat, with high relapse rates and low long-term survival. The ML models showed promise in improving patient prognosis predictions, potentially aiding clinical manage
Gainers Sharps Technology (NASDAQ:STSS) shares rose 193.0% to $0.63 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.8 million. Insmed (NASDAQ:INSM) shares moved upwards by 141.54% to $53.14. The company's market cap stands at $7.8 billion. Calliditas Therapeutics (NASDAQ:CALT) shares moved upwards by 71.09% to $38.36. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out 3 days ago. Predictive Oncology (NASDAQ:POAI) shares moved upwards by 62.45% to $2.55. The company's market cap stands at $10.4 million. Corcept Therapeutics (NASDAQ:CORT) shares rose 22.42% to $33.69. The company's mark